Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Abroad (travel likely)RecruitingPHASE2

Conditions

NSCLC Stage IV · NSCLC, Stage III

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • Olivier BYLICKI, MD, PhD, PR

    Study Director

    HIA Sainte Anne / Groupe Français d'Onco-Pneumologie

  • Laurent GREILLIER, MD, PhD, PR

    Study Director

    AP-HM / Groupe Français d'Onco-Pneumologie